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There is evidence that 5-HTTLPR is associated with response following treatment from selective
serotonin reuptake inhibitors (SSRIs). The short (S) allele has reduced serotonin transporter
expression, compared to the long (L) allele, and has been reported to be associated with poorer
response in Europeans, with the effect in other populations unclear. However the published literature
is inconsistent. A systematic review and meta-analysis was performed to investigate the effect of
5-HTTLPR on discontinuation from antidepressant treatment. Data were obtained from 17 studies
including 4309 participants. The principal outcome measure was the allelic odds ratio (OR) for the 5-
HTTLPR S allele and discontinuation status. A random effects meta-analysis provided no evidence
that the S allele was associated with increased odds of discontinuation from SSRIs in Europeans (OR
1.09, 95% CI 0.83–1.42, p=0.53; 10 studies, n=2504) but in East Asians there was evidence of a
reduced odds of discontinuation (OR 0.28, 95% CI 0.12–0.64, p=0.002; 2 studies, n=136). There was a
suggestion of small study bias (p=0.05). This meta-analysis provides no evidence of an association
between 5-HTTLPR and discontinuation from antidepressant treatment in Europeans. The low
number of studies in East Asian samples using SSRIs reduces conﬁdence in our evidence that the S
allele decreases the odds of discontinuation in this population. At present, there is no evidence of an
association between 5-HTTLPR and discontinuation from SSRI treatment in a European population
with further studies required to investigate its effects in different populations.
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Antidepressants are frequently prescribed in the treatment of
depression. However, long-term treatment is required for
antidepressants to successfully alleviate the symptoms of
depression. Individuals who stop antidepressant treatment
A.A. Crawford et al.1144prematurely may not beneﬁt from treatment and are at a
higher risk of relapse (Montgomery et al., 1993; Donoghue
et al., 1996). The most common reasons for early discontinua-
tion from antidepressant treatment are adverse effects and
lack of efﬁcacy (Demyttenaere et al., 2001). It is not currently
possible to accurately predict who will discontinue treatment.
Variability in antidepressant response has been shown to be
inﬂuenced by both genetic and environmental factors (Uher,
2008) creating the possibility of using genetic biomarkers
capable of predicting discontinuation from treatment.
Selective serotonin reuptake inhibitors (SSRIs) are the ﬁrst
choice antidepressant due to their superior adverse effect
proﬁle. SSRIs increase the levels of serotonin in the synaptic
cleft by binding to the serotonin reuptake transporter (5-HTT),
preventing the reuptake and subsequent storage or degradation
of serotonin. This leads to the accumulation of serotonin in the
synaptic cleft, which in turn may cause adaptive changes in
both serotonergic and noradrenergic neurotransmission and
downstream neural adaptation, helping to alleviate the symp-
toms of depression (Hashimoto, 2009; Vidal et al., 2009). SSRI-
induced side effects may occur when levels of synaptic
serotonin increase to an intolerably high concentration resulting
in over-stimulation of serotonin receptors in the brain and
periphery (Ferguson, 2001).
The serotonin transporter gene-linked polymorphic region
(5-HTTLPR) modulates transcriptional activity of 5-HTT.
5-HTTLPR is a 44 base pair insertion–deletion polymorphism
which can exist as a long (L) variant of a 16 repeat sequence or
a short (S) variant of 14 repeats. The L allele is associated with
higher levels of transcription in vitro compared to the S allele
(Lesch et al., 1996). Therefore, the same dose of SSRI may
inhibit a higher proportion of 5-HTT in individuals carrying the S
allele, causing a rapid accumulation of synaptic serotonin and
increasing the risk of adverse effects, potentially leading to
discontinuation. As studies have associated 5-HTTLPR with
mood disorder (Bellivier et al., 1998; Hauser et al., 2003;
Joiner et al., 2003) and unipolar depression (Clarke et al., 2010)
it is important to distinguish between genuine pharmacogenetic
effects as opposed to effects which simply reﬂect genotype
acting as a marker for disease severity.
The association between 5-HTTLPR and antidepressant
treatment has been subject to numerous studies with the
majority investigating the outcome of response. In general,
data on the number of discontinuations is collected but
rarely published with regards to 5-HTTLPR. Murphy et al.
(2004) found that discontinuation rates due to adverse
effects were lower in patients of European ancestry receiv-
ing paroxetine who were L/L homozygotes. Several studies
have reported that patients with an S allele more frequently
experience adverse effects during treatment with SSRIs
than L allele carriers (Perlis et al., 2003; Maron et al.,
2009; Kato and Serretti, 2010). The largest study to date,
using the STARnD cohort, reported that a lesser burden of
adverse effects from citalopram treatment was associated
with the L allele (Hu et al., 2007). However, the authors
reported no evidence of an association between
5-HTTLPR and intolerance (discontinuation with high
adverse effect score) to citalopram. The second largest
study to date, using the Genome Based Therapeutic Drugs
for Depression (GENDEP) cohort, found no evidence of an
association between 5-HTTLPR genotype and adverse
effects, self-reported adherence or discontinuation withescitalopram or nortriptyline (Huezo-Diaz et al., 2009).
Other studies have also failed to ﬁnd evidence of an
association between 5-HTTLPR variants and adverse reac-
tions induced by various SSRIs including ﬂuvoxamine
(Takahashi et al., 2002; Kato et al., 2006), paroxetine
(Kato et al., 2005; Tanaka et al., 2008) and sertraline (Ng
et al., 2006) or have even reported the SS genotype to be
associated with lower rates of agitation compared to those
with SL/LL genotype (Kronenberg et al., 2007).
These contradictory ﬁndings have possibly occurred
because studies in vivo have not consistently reported the
L allele to be associated with an increase in transporter
binding sites (Murthy et al., 2010). Other polymorphisms
have also been reported to inﬂuence gene expression, in
particular a single nucleotide polymorphism within the L
allele (rs25531). This LG allele may be associated with
reduced transporter expression, in a similar manner to the
S allele (Hu et al., 2006). Additionally, the role of ancestry
may be important. There is a much higher frequency of the
S allele in East Asian (79%) than in European (42%) popula-
tions (Kunugi et al., 1997). The difference in allele fre-
quency has the potential to introduce confounding by
population structure, as well as reducing the power in
studies where the allele frequency is lower. In addition
differences in linkage disequilibrium patterns between
populations may be important if the SNP which is being
studied is a proxy for the one which is inﬂuencing outcome.
There have been several meta-analyses attempting to clarify
the role of 5-HTTLPR in response to antidepressant treatment.
The most recent meta-analysis, which included 33 studies (5479
subjects), concluded that in Europeans 5-HTTLPR may be a
predictor of antidepressant response and remission, while in
East Asians it does not appear to play a major role (Porcelli
et al., 2012). An earlier meta-analysis which included 28 studies
(5408 subjects) concluded that the 5-HTTLPR bi-allelic short/
long polymorphism by itself does not seem to predict anti-
depressant response to a clinically useful degree (Taylor et al.,
2010). These conﬂicting ﬁndings may be due to the inclusion
of different studies as well as stratifying by different factors.
A meta-analysis of 9 studies with 2642 participants found that
the L allele was associated with a reduced risk of experiencing
side effects (Kato and Serretti, 2010).
To build on the work of previous meta-analyses we
decided to investigate the association between 5-HTTLPR
and the number of individuals who discontinue antidepres-
sant treatment. Our outcome of discontinuation includes
individuals who discontinued antidepressant treatment for
any reason. We chose our outcome of discontinuation as it
does not require an individual to make a potentially
complex psychosocial judgement on the reason of disconti-
nuation. Additionally, examining discontinuation is often
used to study comparative acceptability of medication
(Cipriani et al., 2009). Ideally our hypothesis would be
tested by studying rates of adverse effects but unfortu-
nately not all studies collect this data and exclusion of these
studies could introduce bias. Our choice of outcome is
clinically important as individuals who discontinue prema-
turely from antidepressant treatment are unable to beneﬁt
from the treatment and are at greater risk of relapse
(Montgomery et al., 1993; Donoghue et al., 1996). To our
knowledge this is the ﬁrst meta-analysis to use an outcome
of discontinuation from antidepressant treatment.
11455-HTTLPR and Discontinuation of Antidepressant Treatment2. Experimental Procedures
2.1. Selection of studies for inclusion
Studies in which depressed individuals received antidepressant med-
ication and data on discontinuations were reported by 5-HTTLPR
polymorphism status were included. The principal outcome measure
was the allelic odds ratio (OR) for the 5-HTTLPR S allele and
discontinuation status. Ancestry was coded as European, East Asian,
or other. If the study reported results by ancestry or was a randomised
controlled trial (RCT), each population or randomised group was
treated as a separate sample.
2.2. Search strategy
Electronic databases were searched (Embase, Web of Science and
Medline) from the ﬁrst date available in each database up to 18
September 2012 using the search terms ‘‘5-HT’’, ‘‘5-HTT’’, ‘‘SERT’’,
‘‘serotonin’’, ‘‘transporter’’, ‘‘SLC6A4’’, ‘‘5-HTTLPR’’, ‘‘antidepres-
sant’’, ‘‘SSRI’’, ‘‘SRI’’ or ‘‘reuptake inhibitor’’. The full search
strategy is available in Supplementary Figure 1. Studies were also
identiﬁed from earlier reviews. Bibliographies of the collected
articles were then hand-searched for additional references. The
abstracts of the identiﬁed studies were then examined with
reference to the inclusion and exclusion criteria by two researchers
independently. Studies not written in English were translated by a
native speaker. Data extraction was also performed by two indivi-
duals independently. In cases of disagreement over study eligibility
or extraction of data, issues were discussed and a consensus
reached. Studies with overlapping patient samples were identiﬁed
and only the publication with the larger number of patients was
included. Authors of published studies were contacted when the
necessary data for this meta-analysis were not reported, and
included if they provided the data.
2.3. Data analysis
Data were analysed within a random effects (DerSimonian-Laird)
model and the individual and pooled ORs and associated 95%
conﬁdence intervals (CI) were calculated. Random-effects models
are more conservative than ﬁxed-effects models and assume that
the true effect size could vary from study to study. The signiﬁcance
of the pooled OR was determined using a Z-test, and heterogeneity
between studies was assessed with chi-squared goodness of ﬁt and
the I2 statistic. The I2 statistic quantiﬁes the percentage of total
variation across studies due to heterogeneity rather than chance
variation. The higher the I2 statistic, the more between-study
heterogeneity, with the values of 25%, 50%, and 75% considered as
low, moderate, and high heterogeneity, respectively (Higgins et al.,
2003). High between-study heterogeneity indicates potential meth-
odological or sample differences. Our primary analysis compared
the effect of the S allele with the L allele on discontinuation, but
given the lack of unequivocal data for the 5-HTTLPR genetic model,
all models were tested: S allele vs. L allele, S carriers vs. LL,
L carriers vs. SS, and SS vs. LL. If data were available, a secondary
analysis was performed with an outcome of discontinuation due to
adverse effects. We conducted a series of stratiﬁed analyses and
meta-regression analyses to assess the impact of various study
characteristics, including class of antidepressant (SSRI vs. non-
SSRI), ancestry (European vs. East Asian vs. Other), year of
publication, mean sample age, percentage male, study size and
study duration. The genotype distributions for each study were used
to calculate deviation from Hardy–Weinberg equilibrium (HWE)
using a w2 test, and those studies which did show evidence of
deviation were excluded in a sensitivity analysis. An inﬂuence
analysis was also performed to investigate the effects of excludingsingle studies. To assess potential small study bias, as might be
caused by publication bias, a funnel plot was prepared of ln OR
against the SE ln OR (Sterne and Egger, 2001) and analysed using
Egger’s test (Egger et al., 1997). An asymmetric funnel plot
indicates a relationship between treatment effect and study size.
Data were analysed using Stata version 12.1 (StataCorp, 2011). We
report exact p-values throughout.
3. Results
3.1. Description of studies
A total of 17 studies (longitudinal studies (n=11) and RCT’s
(n=6)) (Joyce et al., 2003; Durham et al., 2004; Murphy et al.,
2004; Kato et al., 2005; Kato et al., 2006; Hu et al., 2007; Kang
et al., 2007a; Kang et al., 2007b; Serretti et al., 2007; Dogan
et al., 2008; Gressier et al., 2009; Higuchi et al., 2009; Huezo-
Diaz et al., 2009; Ruhe et al., 2009; Saeki et al., 2009;
Yoshimura et al., 2009; Gudayol-Ferre et al., 2010; Illi et al.,
2010; Lanctot et al., 2010; Safarinejad, 2010; Umene-Nakano
et al., 2010; Yuksel et al., 2010; Illi et al., 2011; Lewis et al.,
2011; StataCorp, 2011), comprising k=22 independent samples
(each arm of the RCT was treated as a separate sample if the
interventions were pharmacologically different and not pla-
cebo. Different ancestries were also treated as separate
samples) published between 2003 and 2011, were identiﬁed
by the search strategy and included in the meta-analysis
(Supplementary Figure 2). A total of 4309 individuals (848
discontinuations) were included and samples varied in size from
30 to 980 individuals. The characteristics of these samples are
presented in Table 1. Of these, k=15 samples were derived
from populations of predominantly European ancestry, k=4
from populations of East Asian ancestry, and k=3 from other
populations. The study by Kato et al. (2006) only provided
genetic data comparing SS homozygotes with L allele carriers
and so had to be excluded from other analyses. All studies
included individuals with a diagnosis of depression, however
one study looked at depressed patients after brain trauma
(Lanctot et al., 2010), and one study also included individuals
with bipolar disorder (Serretti et al., 2007). The study by
Serretti et al. (2007) and a sample from the study by Hu et al.
(2007) deviated from HWE (p=0.03 and po0.001, respectively).
3.2. Meta-analysis
3.2.1. Exploratory analysis
A total of 22 independent samples (4309 individuals in total:
The ‘‘SSRI’’ antidepressant analysis included 16 samples and
3311 individuals; the ‘‘other’’ antidepressants analysis
included 6 samples and 998 individuals) were included. We
found no evidence that the S allele was associated with
discontinuation from antidepressant treatment overall (OR
0.95, 95% CI 0.79–1.14, p=0.55) or in the sub-group analyses
in the SSRI group (OR 0.98, 95% CI 0.77–1.24, p=0.83) or
other antidepressant group (OR 0.88, 95% CI 0.72–1.09,
p=0.24). There was evidence of moderate heterogeneity
(w2[20]=41.67, p=0.003, I
2=52%) which remained when
the SSRI group was considered separately (w2[14]=34.65,
p=0.002, I2=60%). Analysis by different genotype models
did not substantially alter the results (results available on
request). Excluding any individual study, any study not in
Table 1 Characteristics and summary of results of included samples.
Sample Year Sample
size
No. of
dropouts
SS
(%)
Antidepressant Ancestry Mean
Age
Male
(%)
HWE
Joyce (38) 2003 86 11 34 Fluoxetine European 32 44 Yes
Joyce (38) 2003 82 25 27 Nortriptyline European 32 44 Yes
Murphy (13) 2004 121 30 20 Paroxetine European 72 47 Yes
Murphy (13) 2004 123 18 25 Mirtazapine European 72 50 Yes
Durham (36) 2004 101 20 16 Sertraline European 70 47 Yes
Kato (20) 2006 100 20 60 Paroxetine, Fluvoxamine East Asian 44 56 Yes
Hu (17) 2007 420 64 21 Citalopram Other 42 39 No
Hu (17) 2007 980 137 18 Citalopram European 42 39 Yes
Kang (48) 2007 135 34 76 Mirtazapine East Asian 50 29 Yes
Serretti (44) 2007 281 86 24 Fluvoxamine, Paroxetine,
Sertraline
European 49 32 No
Dogan (39) 2008 64 20 33 Sertraline European 37 22 Yes
Yoshimura (42) 2009 71 11 35 Paroxetine East Asian 44 44 Yes
Huezo-Diaz (18) 2009 450 92 17 Escitalopram European 43 38 Yes
Huezo-Diaz (18) 2009 345 94 15 Nortriptyline European 42 35 Yes
Ruhe (43) 2009 51 7 16 Paroxetine European 42 36 Yes
Lewis (35) 2010 273 41 19 Citalopram European 39 36 Yes
Lewis (35) 2010 283 93 17 Reboxetine European 39 34 Yes
Illi (37) 2010 97 12 13 Citalopram, Fluoexetine,
Paroxetine
European 42 42 Yes
Yuksel (41) 2010 30 10 27 Venlafaxine European 37 43 Yes
Umene-Nakano
(45)
2010 65 6 60 Sertraline East Asian 55 37 Yes
Lanctot (46) 2010 79 9 30 Citalopram Other 40 56 Yes
Gudayol Ferre
(47)
2010 72 8 39 Fluoxetine Other 31 8 Yes
Characteristics of included samples is presented, with year, number of subjects, number of discontinuations, percentage (%) of
individuals homozygous with the short (S) 5-HTTLPR allele, type of antidepressant, sample ancestry, mean age, percentage of males in
the sample, and whether the genotype frequencies reported were in approximate Hardy–Weinberg Equilibrium (HWE).
A.A. Crawford et al.1146HWE (Hu et al., 2007; Serretti et al., 2007), or any study
including depressed individuals with another diagnosed
disorder (Serretti et al., 2007; Lanctot et al., 2010), did
not alter our results substantially.3.2.2. Analysis in European individuals
A total of 15 independent samples (3367 individuals in total:
10 samples and 2504 individuals included in the ‘‘SSRI’’
antidepressant analysis; 5 samples and 863 individuals
included in the ‘‘other’’ antidepressants analysis) were
included. We found no evidence that the S allele was
associated with increased odds of discontinuation from anti-
depressant treatment overall (OR 1.00, 95% CI 0.81–1.22,
p=0.96) or in the SSRI group (OR 1.09, 95% CI 0.83–1.42,
p=0.53) or other antidepressant group (OR 0.86, 95% CI 0.68–
1.09, p=0.22). There was evidence of moderate heterogeneity
(w2[14]=30.14, p=0.007, I
2=54%) which remained when the SSRI
group was considered separately (w2[9]=22.22, p=0.008,
I2=60%). These results are displayed graphically in Figure 1.
Analysis by different genotype models did not substantially
alter the results (Supplementary Figures 3–5). Excluding any
individual study, any study not in HWE or any study not
exclusively of depressed individuals did not alter our results
substantially.3.2.3. Analysis in East Asian individuals
A total of 4 independent samples (371 individuals in total:
3 samples and 236 individuals included in the ‘‘SSRI’’ anti-
depressant analysis; 1 sample and 135 individuals included in
the ‘‘other’’ antidepressants analysis) were included. The
study by Kato et al. (2006) only provided genetic data in a
format that allowed inclusion in the analysis comparing SS
homozygotes with L allele carriers (SS vs. SL/LL). We found
evidence that the S allele (S vs. L) was associated with
reduced odds of discontinuation from SSRI treatment (OR
0.28, 95% CI 0.12–0.64, p=0.002; Figure 1). Comparing
homozygote individuals (SS vs. LL) did not alter results
substantially. There was weak statistical evidence of an
association when comparing SS homozygotes with L allele
carriers (OR 0.34, p=0.08), and when comparing LL homo-
zygotes with S allele carriers (LL vs. SL/SS) (OR 0.24,
p=0.14).3.2.4. Discontinuation due to adverse effects
We investigated an outcome of discontinuations speciﬁcally
due to adverse effects in Europeans receiving SSRI treat-
ment (5 independent samples (Murphy et al., 2004; Hu
et al., 2007; Dogan et al., 2008; Ruhe et al., 2009; Illi et al.,
2010), 1307 individuals were included). A per allele analysis
NOTE: Weights are from random effects analysis
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Figure 1 Meta-analysis of association studies of 5-HTTLPR genotype and SSRI discontinuation stratiﬁed by ancestry (European vs.
East Asian vs. Other). Meta-analysis provides no evidence of an association between 5-HTTLPR genotype and SSRI discontinuation for
European studies (z=0.63, p=0.53) for other studies (z=0.51, p=0.61), or overall (z=0.21, p=0.8). There is evidence of an
association between 5-HTTLPR genotype and SSRI discontinuation for East Asian studies (z=3.03, p=0.002). Bars represent individual
study 95% conﬁdence intervals, with a central block proportional to study size. The summary diamond bars represent the pooled
effect size estimate and 95% conﬁdence interval (CI) for the European studies, East Asian studies, other studies and all studies, as
you look from top to bottom.
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2.76, p=0.3; data available by request).
3.2.5. Small study bias
Visual inspection of a funnel plot of all studies indicated
asymmetry, suggesting that some small studies reporting an
association between the S allele and increased risk of
discontinuation may be missing (Supplementary Figure 6).
Egger’s test provided some evidence of small study bias
(p=0.05) when all studies were included, although this test
has low statistical power given the small number of studies.
Evidence of small study bias no longer remained when only
European studies were included (p=0.34). There was no
evidence between individual study effect size estimate and
year of publication (p=0.55), mean sample age (p=0.91),
study size (p=0.32), percentage male (p=0.55) or study
duration (p=0.30) when all studies were included, or when
restricted to European only studies (results available on
request).
4. Discussion
To our knowledge, this is the ﬁrst meta-analysis to assess
the association of 5-HTTLPR genotype with discontinuation
following SSRI treatment. Our results ﬁnd no evidence of an
association between 5-HTTLPR and discontinuation from
SSRI treatment in a European population. This supportsthe ﬁndings from the three largest studies on a predomi-
nantly European population (STARD (Hu et al., 2007),
GENDEP (Huezo-Diaz et al., 2009) and Genetic and clinical
Predictors Of treatment response in Depression (GENPOD)
(Lewis et al., 2011)), suggesting that there is no evidence of
an association between the bi-allelic 5-HTTLPR polymorph-
ism with SSRI discontinuation in Europeans. However, due to
the low number of discontinuation events we are unable
to rule out the possibility of a clinically important effect
with SSRI treatment as the S allele may be associated with
up to a 42% increase in odds of discontinuation or a 17%
reduced odds (OR 1.09, 95% CI 0.83–1.42).
We found some evidence that the S allele decreases the
odds of discontinuation from SSRI treatment in East Asians.
The low number and small size of East Asian studies (only 17
dropouts in the SSRI analysis) included in this meta-analysis
mean that further studies are required to investigate its
effects before we can draw any ﬁrm conclusions. There was
evidence of considerable heterogeneity even within Eur-
opeans treated with an SSRI. The cause of this heterogene-
ity is unknown as there was substantial consistency in the
diagnostic criteria as well as antidepressant agents used.
This meta-analysis investigated the 5-HTTLPR as a bi-
allelic polymorphism only. Ideally polymorphisms such as
rs25531 and VNTR STin2 should be included as these have
also been reported to affect gene expression (Hranilovic
et al., 2004), although the functionality of some of these
variants remains uncertain (Parsey et al., 2006). Other
A.A. Crawford et al.1148polymorphisms were not included in this meta-analysis as
not all studies have the necessary genetic data. From our 17
studies only 6 had the necessary genetic data for rs25531,
and exclusion of the other studies would result in loss of
power and could introduce bias. The largest study to date
reported an analysis in which individuals were differen-
tiated according to the presence of the LA allele, this
stratiﬁcation did not substantially alter results when analys-
ing the whole STARD sample. However, it did alter the
results of a sub-group analysis of white, non-Hispanic
individuals with adverse effect burden as the outcome (Hu
et al., 2007).
Commonly cited reasons for discontinuing antidepressant
treatment are due to adverse effects or lack of efﬁcacy. The
evidence from the two most recent meta-analyses investi-
gating these outcomes (adverse effects (Kato and Serretti,
2010), response (Porcelli et al., 2012)) suggests that the L
allele is associated with a reduced risk of experiencing
adverse effects, and with increased odds of responding to
SSRI treatment. However, we found no evidence for an
association between the L allele and reduced odds of
discontinuation. There are multiple reasons why an indivi-
dual may choose to stop antidepressant treatment, not
associated with antidepressant response or adverse effects,
such as fear of drug dependency. Therefore, our outcome of
all discontinuations may have been too broad to ﬁnd
evidence of an association with 5-HTTLPR. However, our
analysis of discontinuation due to adverse effects also found
no evidence of an association with 5-HTTLPR. The low
number of independent samples with data on reason of
discontinuation mean this analysis lacked the power to
detect a potentially important effect and further work
could focus on discontinuation speciﬁcally due to adverse
effects or lack of efﬁcacy.
As mentioned previously the low number of Asian studies
included in this meta-analysis mean we are currently unable
to determine the effect of this polymorphism in an East
Asian population. However, the results of this meta-analysis
summarise the available data on SSRI-discontinuation and 5-
HTTLPR in a European population. At present, there is no
evidence of an association between 5-HTTLPR and disconti-
nuation from SSRI treatment in a European population. The
lack of precision in our effect estimate (indicated by our
wide 95% CI) highlights the need for greater research in this
area before we can make any deﬁnite conclusions on its
potential clinical importance. A meta-analysis of approxi-
mately 5400 European individuals would be required to
determine whether 5-HTTLPR has at least a 15% change in
risk of discontinuation from SSRI treatment. Future studies
should report adverse effects and discontinuation alongside
the more customary efﬁcacy measurements in order to
improve our knowledge of the 5-HTTLPR and its effect on
outcomes following antidepressant treatment.Role of funding source
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